Fig. 1From: Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosisDescription of different components of no evidence of disease activity (NEDA-3) at the end of the 24-month follow-up in 196 patients with relapsing-remitting multiple sclerosis treated with fingolimodBack to article page